Tilray is supplying medical cannabis to pediatric patient in need
NANAIMO, British Columbia--(BUSINESS WIRE)--Sep. 11, 2018--
Tilray
Inc. (NASDAQ:TLRY), a global leader in cannabis research, production and
distribution, announced today that Tilray 2:100, a product produced at
Tilray’s federally licensed, Good Manufacturing Practice (GMP)-certified
facility in Canada, was successfully imported into the United Kingdom,
to supply a pediatric patient in need.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180911005234/en/
Tilray 2:100 (Photo: Business Wire)
The changing regulatory measures in the United Kingdom (UK) previously
prohibited the use of medical cannabis. However, in July 2018, Home
Secretary Sajid Javidannounced
that clinicians will now legally be able to prescribe cannabis-derived
medicines to patients with an exceptional clinical need noting “recent
cases involving sick children made it clear to me that our position on
cannabis-related medicinal products was not satisfactory.”
With government-approved compassionate access, the UK-based patient
suffering from a rare form of epilepsy, now has reliable access to
Tilray 2:100, the product used as the primary medicine in a clinical
trial testing the efficacy and tolerability of cannabis-derived medicine
as treatment for pediatric epilepsy. The trial was conducted in
partnership with The Hospital For Sick Children (SickKids) in Toronto,
Canada and published promising
results in August.
In a press release issued by SickKids, Dr. Blathnaid McCoy, Staff
Neurologist at SickKids who conducted the clinical trial and authored
the research, said “In the participants who reached the target treatment
dose we saw a statistically significant reduction in motor seizures, and
an increase in seizure-free days compared to those who did not reach the
target dose. We observed promising clinically beneficial effects
including a reduction in seizure frequency and improvements in certain
aspects of adaptive functioning and quality of life measures.”
The Tilray oral solution imported to the United Kingdom contains 100
mg/ml cannabidiol (CBD) and 2mg/ml tetrahydrocannabinol (THC), the same
ratio of active cannabinoids Tilray used in the recent clinical trial
led by SickKids. This ratio of the active cannabinoids was selected
after Tilray conducted extensive research on published data of
cannabinoids to treat seizures. Tilray 2:100 was deemed safe and well
tolerated in pediatric patients by the researchers.
About Tilray®
Tilray is
a global pioneer in the research, cultivation, production and
distribution of cannabis and cannabinoids currently serving tens of
thousands of patients in eleven countries spanning five continents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180911005234/en/
Source: Tilray Inc.
For Tilray
Media:
US & Canada
Chrissy
Roebuck, +1-416-560-5712
chrissy.roebuck@tilray.com
or
UK
Justin
Doherty, +44 (0)7768-330223
jd@hemingtonconsulting.co.uk
or
Investors:
Katie
Turner, +1-646-277-1228
Katie.turner@icrinc.com